MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1021/acs.jmedchem.8b01819

Медицинская библиотека · Journal of medicinal chemistry · 2019

Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington's Disease Models.

Toledo-Sherman Leticia, Breccia Perla, Cachope Roger, Bate Jennifer R, Angulo-Herrera Ivan, Wishart Grant, Matthews Kim L, Martin Sarah L, Cox Helen C, McAllister George, Penrose Stephen D, Vater Huw, Esmieu William, Van de Poël Amanda, Van de Bospoort Rhea, Strijbosch Annelieke, Lamers Marieke, Leonard Philip, Jarvis Rebecca E, Blackaby Wesley, Barnes Karen, Eznarriaga Maria, Dowler Simon, Smith Graham D, Fischer David F, Lazari Ovadia, Yates Dawn, Rose Mark, Jang Sung-Wook, Muñoz-Sanjuan Ignacio, Dominguez Celia

СтатьяПеревод пока не подготовлен

Аннотация

Genetic and pharmacological evidence indicates that the reduction of ataxia telangiectasia-mutated (ATM) kinase activity can ameliorate mutant huntingtin (mHTT) toxicity in cellular and animal models of Huntington's disease (HD), suggesting that selective inhibition of ATM could provide a novel clinical intervention to treat HD. Here, we describe the development and characterization of ATM inhibitor molecules to enable in vivo proof-of-concept studies in HD animal models. Starting from previously reported ATM inhibitors, we aimed with few modifications to increase brain exposure by decreasing P-glycoprotein liability while maintaining potency and selectivity. Here, we report brain-penetrant ATM inhibitors that have robust pharmacodynamic (PD) effects consistent with ATM kinase inhibition in the mouse brain and an understandable pharmacokinetic/PD (PK/PD) relationship. Compound 17 engages ATM kinase and shows robust dose-dependent inhibition of X-ray irradiation-induced KAP1 phosphorylation in the mouse brain. Furthermore, compound 17 protects against mHTT (Q73)-induced cytotoxicity in a cortical-striatal cell model of HD.

Для цитирования: Toledo-Sherman Leticia, Breccia Perla, Cachope Roger, Bate Jennifer R, Angulo-Herrera Ivan, Wishart Grant, Matthews Kim L, Martin Sarah L, Cox Helen C, McAllister George, Penrose Stephen D, Vater Huw, Esmieu William, Van de Poël Amanda, Van de Bospoort Rhea, Strijbosch Annelieke, Lamers Marieke, Leonard Philip, Jarvis Rebecca E, Blackaby Wesley, Barnes Karen, Eznarriaga Maria, Dowler Simon, Smith Graham D, Fischer David F, Lazari Ovadia, Yates Dawn, Rose Mark, Jang Sung-Wook, Muñoz-Sanjuan Ignacio, Dominguez Celia. Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington's Disease Models.. Journal of medicinal chemistry. 2019. DOI: 10.1021/acs.jmedchem.8b01819.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.